U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H42O19
Molecular Weight 742.6752
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TROXERUTIN

SMILES

C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=C(C3=O)C(O)=CC(OCCO)=C4)C5=CC=C(OCCO)C(OCCO)=C5)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O

InChI

InChIKey=IYVFNTXFRYQLRP-VVSTWUKXSA-N
InChI=1S/C33H42O19/c1-14-23(38)26(41)28(43)32(49-14)48-13-21-24(39)27(42)29(44)33(51-21)52-31-25(40)22-17(37)11-16(45-7-4-34)12-20(22)50-30(31)15-2-3-18(46-8-5-35)19(10-15)47-9-6-36/h2-3,10-12,14,21,23-24,26-29,32-39,41-44H,4-9,13H2,1H3/t14-,21+,23-,24+,26+,27-,28+,29+,32+,33-/m0/s1

HIDE SMILES / InChI

Molecular Formula C33H42O19
Molecular Weight 742.6752
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Troxerutin (TXN) is a flavonoid present in tea, coffee, cereal grains, and a variety of fruits and vegetables. It inhibits the agglomeration of blood platelets and red blood cells; prevents thrombogenesis; protects endothelial cells; and enhances microcirculation. It possess anti-inflammatory and anti-apoptotic properties. Troxerutin protected different cell types (epithelial cells, fibroblasts and lymphocytes) against peroxyl radical-induced apoptosis, necrosis and mitotic death. It scavenged intracellular basal and inducible ROS levels and also restored depletion of intracellular GSH levels. Troxerutin might provide a safe and effective treatment for rhinorrhea in the common cold deserves systematic evaluation. The use of a mixture of troxerutin, diosmin and hesperidin is a safe and effective mean of managing symptoms of acute hemorrhoidal disease. Troxerutin is used for the treatment of chronic venous insufficiency.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Palliative
Unknown
Primary
Unknown
Palliative
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
180 mg fixed-dose three times daily for up to 16 weeks.
Route of Administration: Oral
In Vitro Use Guide
Different concentrations (0,31.25, 62.5, 125, 250, 500, 750 & 1000 uM) of Troxerutin (TXER) was challenged against constant concentration of Cu (100 uM). 2.5:1 ratio of TXER+Cu shows maximum inhibitory effect on Huh-7 cells, which is statistically significant (P<0.05). A similar trend was observed when both the concentration was increased.
Substance Class Chemical
Record UNII
7Y4N11PXO8
Record Status Validated (UNII)
Record Version